FDA Expands Eligibility for Bivalent COVID-19 Vaccines Ahead of Fall Campaigns

The U.S. Food and Drug Administration (FDA) has revised its emergency use authorizations for the Pfizer and Moderna bivalent COVID-19 vaccines, allowing individuals aged 65 and older, along with certain immunocompromised individuals, to receive additional doses. This adjustment aims to enhance protection ahead of anticipated vaccination drives this fall.

Why It Matters

This development is critical as health officials strive to boost immunity levels among the most vulnerable populations. With evidence suggesting waning effectiveness of the bivalent vaccines, particularly among older adults and those with weakened immune systems, the FDA’s decision is a response to ongoing concerns regarding COVID-19 risks and hospitalizations.

Key Developments

• Eligibility for Additional Doses: Adults aged 65 and older can receive a second dose of a bivalent vaccine at least four months after their initial dose. Immunocompromised individuals may get a second dose two months after their first.

• Simplified Guidance for Unvaccinated: Unvaccinated individuals may now receive a single dose of a bivalent vaccine instead of needing multiple doses of the original vaccines.

• Children’s Dosing Updates: Children aged 6 months to 4 years can now receive a tailored two or three-dose series of the bivalent vaccines, depending on previous vaccinations.

• Immunity Landscape: The FDA acknowledges that the majority of the U.S. population over the age of five likely has some level of immunity against COVID-19, making the new recommendations more viable.

• ACIP Meeting Scheduled: The FDA is expected to gain additional insights on bivalent vaccine recommendations from the Advisory Committee on Immunization Practices during a meeting soon.

Full Report

Changes in Vaccine Authorization

On Tuesday, the FDA updated its emergency use authorizations for the Pfizer and Moderna bivalent vaccines, paving the way for older adults and certain immunocompromised groups to receive extra doses ahead of important vaccination initiatives planned for this fall. These bivalent vaccines target both the original strain of COVID-19 and the Omicron variants, enhancing their effectiveness in combating the virus.

Certain adults aged 65 and older who have received one bivalent vaccine dose are now eligible for another dose, while many immunocompromised individuals can receive additional doses as recommended by their healthcare providers. Dr. Peter Hotez, a prominent figure in vaccine development, expressed support for the FDA’s guidance but questioned the age cutoff, suggesting that it should be lowered to include those aged 60 or even 50.

New Recommendations for Unvaccinated Individuals

Further simplifying the vaccination process, the FDA has determined that most unvaccinated people now qualify for a single dose of a bivalent vaccine, rather than requiring them to receive multiple original vaccines. This change reflects the agency’s acknowledgment of the widespread immunity present in the population, either from previous infections or vaccinations.

Dr. Peter Marks, head of FDA’s Center for Biologics Evaluation and Research, emphasized that while many people have some level of protection, vaccination remains critical in preventing severe outcomes, including hospitalization and death.

Updates for Young Children

Children aged 6 months to 5 years are now eligible for specific doses of the bivalent vaccines based on their previous vaccination history. Those who began with monovalent vaccines can now receive a bivalent dose, though the number will depend on their vaccination record.

Despite these updates, the FDA has cautioned that the majority of individuals who have received one bivalent dose are not yet eligible for a second dose. This highlights a significant gap, as only about 17% of those eligible for bivalent vaccinations have received their recommended doses to date.

Context & Previous Events

Since September, the bivalent vaccines have been authorized for emergency use in the United States, but the previous restrictions limited how these vaccines could be administered. Based on early data suggesting the waning effectiveness of the bivalent vaccines, and the challenges faced by immunocompromised populations, the FDA’s latest revisions aim to provide more comprehensive access to critical booster shots. The agency has noted that discussions about additional annual boosters will take place this summer, further addressing ongoing vaccination strategies. Meanwhile, other countries, including Canada and the United Kingdom, have already initiated additional rounds of bivalent boosters for high-risk individuals.